MedTrace Logo

Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy

NCT03201913 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-08-11

No results posted yet for this study

Summary

Phase1 study of TTC 352 for treatment of metastatic ER+ breast cancer.

Conditions

  • Metastatic ER+ Breast Cancer

Interventions

DRUG

TTC-352

Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.

Sponsors & Collaborators

  • TTC Oncology, LLC

    lead INDUSTRY

Principal Investigators

  • Arkadiusz Z Dudek, MD · TTC Oncology, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-11
Primary Completion
2019-12-31
Completion
2020-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03201913 on ClinicalTrials.gov